Literature DB >> 29248242

Plasma microbiome-modulated indole- and phenyl-derived metabolites associate with advanced atherosclerosis and postoperative outcomes.

Cori A Cason1, Kyle T Dolan2, Gaurav Sharma3, Ming Tao3, Rohan Kulkarni4, Irene B Helenowski5, Brendan M Doane6, Michael J Avram6, Mary M McDermott7, Eugene B Chang2, C Keith Ozaki3, Karen J Ho8.   

Abstract

OBJECTIVE: Multiple studies have shown that gut microbes contribute to atherosclerosis, and there is mounting evidence that microbial metabolism of dietary nutrients influences pathophysiology. We hypothesized that indole- and phenyl-derived metabolites that originate solely or in part from bacterial sources would differ between patients with advanced atherosclerosis and age- and sex-matched controls without clinically apparent atherosclerosis.
METHODS: Plasma from the advanced atherosclerosis cohort (n = 100) was from patients who underwent carotid endarterectomy, open infrainguinal leg revascularization, or major leg amputation for critical limb ischemia. The controls (n = 22) were age- and sex-matched participants who had no peripheral arterial disease or history of stroke or myocardial infarction. Patients with chronic kidney disease were excluded. Metabolites and internal standards were measured using high-performance liquid chromatography and tandem mass spectrometry.
RESULTS: Plasma metabolite concentrations differed significantly between the advanced atherosclerosis and control cohorts. After adjustment for traditional atherosclerosis risk factors, indole (odds ratio [OR], 0.84; 95% confidence interval [CI], 0.75-0.95; P = .004), tryptophan (OR, <0.001; 95% CI, <0.001-0.003; P < .001), indole-3-propionic acid (OR, 0.27; 95% CI, 0.019-0.91; P = .02), and indole-3-aldehyde (OR, 0.12; 95% CI, 0.014-0.92; P = .04) concentrations negatively associated with advanced atherosclerosis, whereas the kynurenine/tryptophan ratio (OR, 61.7; 95% CI, 1.9->999; P = .02) was positively associated. Furthermore, tryptophan and indole-3-propionic acid concentrations (Spearman coefficients of 0.63 and 0.56, respectively; P < .001) correlated with the ankle-brachial index, a surrogate for overall atherosclerotic disease burden. Fourteen patients experienced a major postoperative cardiac complication within 30 days in the advanced atherosclerosis cohort, which was associated with baseline kynurenine/tryptophan ratio (P = .001) and hippuric acid (P = .03). In a multivariate analysis, only the kynurenine/tryptophan ratio remained significantly associated with a postoperative cardiac complication (OR, 44.1; 95% CI, 3.3-587.1; P = .004). Twenty patients in the advanced atherosclerosis cohort experienced a major adverse cardiac event during the follow-up period, which was associated with hippuric acid (P = .002) and the kynurenine/tryptophan ratio (P < .001) at baseline. Both hippuric acid and the kynurenine/tryptophan ratio were independently associated with a major adverse cardiac event in multivariate analyses that included diabetes mellitus.
CONCLUSIONS: Specific microbe-derived metabolite signatures associate with advanced human atherosclerosis and postoperative cardiac complications. We suggest that these metabolites are potential novel biomarkers for atherosclerotic disease burden and that further investigation into mechanistic links between defined microbial metabolic pathways and cardiovascular disease is warranted.
Copyright © 2017 Society for Vascular Surgery. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29248242      PMCID: PMC5999545          DOI: 10.1016/j.jvs.2017.09.029

Source DB:  PubMed          Journal:  J Vasc Surg        ISSN: 0741-5214            Impact factor:   4.268


  51 in total

1.  Inhibition of the accumulation of uremic toxins in the blood and their precursors in the feces after oral administration of Lebenin, a lactic acid bacteria preparation, to uremic patients undergoing hemodialysis.

Authors:  M Hida; Y Aiba; S Sawamura; N Suzuki; T Satoh; Y Koga
Journal:  Nephron       Date:  1996       Impact factor: 2.847

2.  Indoleamine 2,3-dioxygenase-1 is protective in atherosclerosis and its metabolites provide new opportunities for drug development.

Authors:  Jennifer E Cole; Nagore Astola; Adam P Cribbs; Michael E Goddard; Inhye Park; Patricia Green; Alun H Davies; Richard O Williams; Marc Feldmann; Claudia Monaco
Journal:  Proc Natl Acad Sci U S A       Date:  2015-10-05       Impact factor: 11.205

3.  A metagenome-wide association study of gut microbiota in type 2 diabetes.

Authors:  Junjie Qin; Yingrui Li; Zhiming Cai; Shenghui Li; Jianfeng Zhu; Fan Zhang; Suisha Liang; Wenwei Zhang; Yuanlin Guan; Dongqian Shen; Yangqing Peng; Dongya Zhang; Zhuye Jie; Wenxian Wu; Youwen Qin; Wenbin Xue; Junhua Li; Lingchuan Han; Donghui Lu; Peixian Wu; Yali Dai; Xiaojuan Sun; Zesong Li; Aifa Tang; Shilong Zhong; Xiaoping Li; Weineng Chen; Ran Xu; Mingbang Wang; Qiang Feng; Meihua Gong; Jing Yu; Yanyan Zhang; Ming Zhang; Torben Hansen; Gaston Sanchez; Jeroen Raes; Gwen Falony; Shujiro Okuda; Mathieu Almeida; Emmanuelle LeChatelier; Pierre Renault; Nicolas Pons; Jean-Michel Batto; Zhaoxi Zhang; Hua Chen; Ruifu Yang; Weimou Zheng; Songgang Li; Huanming Yang; Jian Wang; S Dusko Ehrlich; Rasmus Nielsen; Oluf Pedersen; Karsten Kristiansen; Jun Wang
Journal:  Nature       Date:  2012-09-26       Impact factor: 49.962

Review 4.  Kynurenines in the CNS: recent advances and new questions.

Authors:  László Vécsei; Levente Szalárdy; Ferenc Fülöp; József Toldi
Journal:  Nat Rev Drug Discov       Date:  2012-12-14       Impact factor: 84.694

5.  GCN2 kinase in T cells mediates proliferative arrest and anergy induction in response to indoleamine 2,3-dioxygenase.

Authors:  David H Munn; Madhav D Sharma; Babak Baban; Heather P Harding; Yuhong Zhang; David Ron; Andrew L Mellor
Journal:  Immunity       Date:  2005-05       Impact factor: 31.745

6.  Superficial femoral artery plaque, the ankle-brachial index, and leg symptoms in peripheral arterial disease: the walking and leg circulation study (WALCS) III.

Authors:  Mary M McDermott; Kiang Liu; James Carr; Michael H Criqui; Lu Tian; Debiao Li; Luigi Ferrucci; Jack M Guralnik; Christopher M Kramer; Chun Yuan; Melina Kibbe; William H Pearce; Jarett Berry; Walter McCarthy; Yihua Liao; Dongxiang Xu; Jennifer Orozco; Timothy J Carroll
Journal:  Circ Cardiovasc Imaging       Date:  2011-03-24       Impact factor: 7.792

Review 7.  Relationship between interferon-gamma, indoleamine 2,3-dioxygenase, and tryptophan catabolism.

Authors:  M W Taylor; G S Feng
Journal:  FASEB J       Date:  1991-08       Impact factor: 5.191

Review 8.  Hippurate: the natural history of a mammalian-microbial cometabolite.

Authors:  Hannah J Lees; Jonathan R Swann; Ian D Wilson; Jeremy K Nicholson; Elaine Holmes
Journal:  J Proteome Res       Date:  2013-03-06       Impact factor: 4.466

9.  Defective tryptophan catabolism underlies inflammation in mouse chronic granulomatous disease.

Authors:  Luigina Romani; Francesca Fallarino; Antonella De Luca; Claudia Montagnoli; Carmen D'Angelo; Teresa Zelante; Carmine Vacca; Francesco Bistoni; Maria C Fioretti; Ursula Grohmann; Brahm H Segal; Paolo Puccetti
Journal:  Nature       Date:  2008-01-10       Impact factor: 49.962

10.  Butyrate and propionate protect against diet-induced obesity and regulate gut hormones via free fatty acid receptor 3-independent mechanisms.

Authors:  Hua V Lin; Andrea Frassetto; Edward J Kowalik; Andrea R Nawrocki; Mofei M Lu; Jennifer R Kosinski; James A Hubert; Daphne Szeto; Xiaorui Yao; Gail Forrest; Donald J Marsh
Journal:  PLoS One       Date:  2012-04-10       Impact factor: 3.240

View more
  28 in total

1.  Serum metabolic signatures of subclinical atherosclerosis in patients with type 2 diabetes mellitus: a preliminary study.

Authors:  Jiaorong Su; Qing Zhao; Aihua Zhao; Wei Jia; Wei Zhu; Jingyi Lu; Xiaojing Ma
Journal:  Acta Diabetol       Date:  2021-04-19       Impact factor: 4.280

Review 2.  Current State of Knowledge on Implications of Gut Microbiome for Surgical Conditions.

Authors:  Edmund B Chen; Cori Cason; Jack A Gilbert; Karen J Ho
Journal:  J Gastrointest Surg       Date:  2018-04-05       Impact factor: 3.452

3.  Microbial metabolite indole-3-propionic acid supplementation does not protect mice from the cardiometabolic consequences of a Western diet.

Authors:  Dustin M Lee; Kayl E Ecton; S Raj J Trikha; Scott D Wrigley; Keely N Thomas; Micah L Battson; Yuren Wei; Sarah A Johnson; Tiffany L Weir; Christopher L Gentile
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2020-05-18       Impact factor: 4.052

4.  Microbiota composition modulates inflammation and neointimal hyperplasia after arterial angioplasty.

Authors:  Cori A Cason; Thomas M Kuntz; Edmund B Chen; Kelly Wun; Michael J Nooromid; Liqun Xiong; Neil R Gottel; Katharine G Harris; Timothy C Morton; Michael J Avram; Eugene B Chang; Jack A Gilbert; Karen J Ho
Journal:  J Vasc Surg       Date:  2020-02-05       Impact factor: 4.268

Review 5.  Microbiota-derived tryptophan metabolites in vascular inflammation and cardiovascular disease.

Authors:  Nadja Paeslack; Maximilian Mimmler; Stefanie Becker; Zhenling Gao; My Phung Khuu; Amrit Mann; Frano Malinarich; Tommy Regen; Christoph Reinhardt
Journal:  Amino Acids       Date:  2022-04-22       Impact factor: 3.520

6.  Beyond Diagnosis: a Novel Microbiota Dependent Biomarker and Target for Atherosclerosis.

Authors:  Di Lang
Journal:  Circ Res       Date:  2022-08-18       Impact factor: 23.213

Review 7.  The potential of tailoring the gut microbiome to prevent and treat cardiometabolic disease.

Authors:  Rima Mohsen Chakaroun; Lisa M Olsson; Fredrik Bäckhed
Journal:  Nat Rev Cardiol       Date:  2022-10-14       Impact factor: 49.421

Review 8.  Interactions between Tryptophan Metabolism, the Gut Microbiome and the Immune System as Potential Drivers of Non-Alcoholic Fatty Liver Disease (NAFLD) and Metabolic Diseases.

Authors:  Charlotte Teunis; Max Nieuwdorp; Nordin Hanssen
Journal:  Metabolites       Date:  2022-06-02

Review 9.  Gut microbiome and cardiometabolic risk.

Authors:  Ben Arpad Kappel; Massimo Federici
Journal:  Rev Endocr Metab Disord       Date:  2019-12       Impact factor: 6.514

Review 10.  Gut microbes in cardiovascular diseases and their potential therapeutic applications.

Authors:  Ling Jin; Xiaoming Shi; Jing Yang; Yangyu Zhao; Lixiang Xue; Li Xu; Jun Cai
Journal:  Protein Cell       Date:  2020-09-28       Impact factor: 14.870

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.